Newsbenzinga
What's Going on With Cue Biopharma Stock on Monday?
· Published
Article summary
Cue Biopharma reports Phase 2 CUE-221 trial results in chronic hives, showing strong efficacy and favorable safety.
An excerpt from the original article.Cue Biopharma reports Phase 2 CUE-221 trial results in chronic hives, showing strong efficacy and favorable safety.
An excerpt from the original article.
Comments —
Loading comments…